Best of the Week
Most Popular
1. TESLA! Cathy Wood ARK Funds Bubble BURSTS! - 12th May 21
2.Stock Market Entering Early Summer Correction Trend Forecast - 10th May 21
3.GOLD GDX, HUI Stocks - Will Paradise Turn into a Dystopia? - 11th May 21
4.Crypto Bubble Bursts! Nicehash Suspends Coinbase Withdrawals, Bitcoin, Ethereum Bear Market Begins - 16th May 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.Cathy Wood Ark Invest Funds Bubble BURSTS! ARKK, ARKG, Tesla Entering Severe Bear Market - 13th May 21
7.Stock Market - Should You Be In Cash Right Now? - 17th May 21
8.Gold to Benefit from Mounting US Debt Pile - 14th May 21
9.Coronavius Covid-19 in Italy in August 2019! - 13th May 21
10.How to Invest in HIGH RISK Tech Stocks for 2021 and Beyond - Part 2 of 2 - 18th May 21
Last 7 days
US Economy and Stock Market Addicted to Deficit Spending - 17th Oct 21
The Gold Price And Inflation - 17th Oct 21
Went Long the Crude Oil? Beware of the Headwinds Ahead… - 17th Oct 21
Watch These Next-gen Cloud Computing Stocks - 17th Oct 21
Overclockers UK Custom Built PC 1 YEAR Use Review Verdict - Does it Still Work? - 16th Oct 21
Altonville Mine Tours Maze at Alton Towers Scarefest 2021 - 16th Oct 21
How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
The Only way to Crush Inflation (not stocks) - 14th Oct 21
Why "Losses Are the Norm" in the Stock Market - 14th Oct 21
Sub Species Castle Maze at Alton Towers Scarefest 2021 - 14th Oct 21
Which Wallet is Best for Storing NFTs? - 14th Oct 21
Ailing UK Pound Has Global Effects - 14th Oct 21
How to Get 6 Years Life Out of Your Overclocked PC System, Optimum GPU, CPU and MB Performance - 13th Oct 21
The Demand Shock of 2022 - 12th Oct 21
4 Reasons Why NFTs Could Be The Future - 12th Oct 21
Crimex Silver: Murder Most Foul - 12th Oct 21
Bitcoin Rockets In Preparation For Liftoff To $100,000 - 12th Oct 21
INTEL Tech Stock to the MOON! INTC 2000 vs 2021 Market Bubble WARNING - 11th Oct 21
AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
Stock Market Wall of Worry Meets NFPs - 11th Oct 21
Stock Market Intermediate Correction Continues - 11th Oct 21
China / US Stock Markets Divergence - 10th Oct 21
Can US Save Taiwan From China? Taiwan Strait Naval Battle - PLA vs 7th Fleet War Game Simulation - 10th Oct 21
Gold Price Outlook: The Inflation Chasm Between Europe and the US - 10th Oct 21
US Real Estate ETFs React To Rising Housing Market Mortgage Interest Rates - 10th Oct 21
US China War over Taiwan Simulation 2021, Invasion Forecast - Who Will Win? - 9th Oct 21
When Will the Fed Taper? - 9th Oct 21
Dancing with Ghouls and Ghosts at Alton Towers Scarefest 2021 - 9th Oct 21
Stock Market FOMO Going into Crash Season - 8th Oct 21
Scan Computers - Custom Build PC 6 Months Later, Reliability, Issues, Quality of Tech Support Review - 8th Oct 21
Gold and Silver: Your Financial Main Battle Tanks - 8th Oct 21
How to handle the “Twin Crises” Evergrande and Debt Ceiling Threatening Stocks - 8th Oct 21
Why a Peak in US Home Prices May Be Approaching - 8th Oct 21
Alton Towers Scarefest is BACK! Post Pandemic Frights Begin, What it's Like to Enter Scarefest 2021 - 8th Oct 21
AJ Bell vs II Interactive Investor - Which Platform is Best for Buying US FAANG Stocks UK Investing - 7th Oct 21
Gold: Evergrande Investors' Savior - 7th Oct 21
Here's What Really Sets Interest Rates (Not Central Banks) - 7th Oct 21
CISCO 2020 Dot com Bubble Stock vs 2021 Bubble Tech Stocks Warning Analysis - 6th Oct 21
Precious Metals Complex Searching for a Bottom - 6th Oct 21
FB, AMZN, NFLX, GOOG, AAPL and FANG+ '5 Waves' Speaks Volumes - 6th Oct 21
Budgies Flying Ability 10 Weeks After wings Clipped, Flight Feathers Cut Grow Back - 6th Oct 21
Why Silver Price Could Crash by 20%! - 5th Oct 21
Will China's Crackdown Send Bitcoin's Price Tumbling? - 5th Oct 21
Natural Gas News: Europe Lacks Supply, So It Turns to Asia - 5th Oct 21
Stock Market Correction: One More Spark to Light the Fire? - 5th Oct 21
Fractal Design Meshify S2, Best PC Case Review, Build Quality, Airflow etc. - 5th Oct 21
Chasing Value with Five More Biotech Stocks for the Long-run - 4th Oct 21
Gold’s Century - While stocks dominated headlines, gold quietly performed - 4th Oct 21
NASDAQ Stock Market Head-n-Shoulders Warns Of Market Weakness – Critical Topping Pattern - 4th Oct 21
US Dollar on plan, attended by the Gold/Silver ratio - 4th Oct 21
Aptorum Group - APM - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run - 3rd Oct 21
US Close to Hitting the Debt Ceiling: Gold Doesn’t Care - 3rd Oct 21
Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
Original Oculus VR HeadSet Rift Dev Kit v1 Before Facebook Bought Oculus - 3rd Oct 21
Microsoft Stock Valuation 2021 vs 2000 Bubble - Buy Sell or Hold Invest Analysis - 1st Oct 21
How to profit off the Acquisition spree in Fintech Stocks - 1st Oct 21
�� Halloween 2021 TESCO Shopping Before the Next Big Panic Buying! �� - 1st Oct 2
The Guide to Building a Design Portfolio Online - 1st Oct 21
BioDelivery Sciences International - BDSI - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run - 30th Sep 21
America’s Revolving-Door Politics Behind the Fall of US-Sino Ties - 30th Sep 21
Dovish to Hawkish Fed: Sounds Bearish for Gold - 30th Sep 21
Stock Market Gauntlet to the Fed - 30th Sep 21
Should you include ESG investments in your portfolio? - 30th Sep 21
Takeda - TAK - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run - 29th Sep 21
Stock Market Wishing Away Inflation - 29th Sep 21
Why Workers Are NOT Returning to Work as Lockdown's End - Wage Slaves Rebellion - 29th Sep 21
UK Fuel PANIC! Fighting at the Petrol Pumps! As Lemmings Create a New Crisis - 29th Sep 21
Gold Could See Tapering as Soon as November! - 29th Sep 21

Market Oracle FREE Newsletter

Category: BioTech

The analysis published under this category are as follows.

Companies

Thursday, December 11, 2014

Genetic Cures for Disease: Impossible Biotech Dream Come True? / Companies / BioTech

By: TLSReport

Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients. In this interview with The Life Sciences Report, David Nierengarten of Wedbush Securities explores gene therapies that actually correct an inborn mutation in human DNA, creating permanent change, actual cures and better lives for patients. It sounds beyond the reach of medicine . . . and therein lies the opportunity: Investors in gene therapy companies may capture serious returns on risk capital when the cure is attained.

Read full article... Read full article...

 


Companies

Tuesday, December 02, 2014

Bio-Tech Stock That Will Profit from a New Breakthrough Medical Direction / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: Modern medicine, for all of its sophisticated drugs, complex gadgets, and amazing surgical procedures, rarely cures anything. It treats. It manages. It postpones the inevitable.

But return a patient to normal, optimal health?

Read full article... Read full article...

 


Companies

Friday, November 21, 2014

Two Biotech Stocks Set to Double on One Powerful Catalyst / Companies / BioTech

By: Money_Morning

William Patalon writes: When I earned my MBA from the Rochester Institute of Technology (RIT) back in the mid-1990s, my focus was finance and investing.

But it was a management professor who clued me in to some of the best ways to "look past the numbers" and understand what really makes a big company tick.

The professor, Janet C. Barnard, retired a few years back and, sadly, passed away in 2012.

Read full article... Read full article...

 


Companies

Friday, October 24, 2014

Natus Medical Justifies Recent Run With Record Q3 Results / Companies / BioTech

By: Submissions

Nicholas Maithya writes: Natus Medical (NASDAQ:BABY) is up more than 125% over the last twelve months and based on recent results, that run seems fully justified with room left for more. The stock closed at $33.51 on Thursday 23, up 2.16% for the day following its impressive results released on the previous day.

Read full article... Read full article...

 


Companies

Thursday, October 23, 2014

Japan Gives a Hug to the Cell Therapy Biotech Industry / Companies / BioTech

By: TLSReport

Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report, former regenerative medicine consultant R. Lee Buckler, now a vice president with RepliCel Life Sciences Inc., puts his consultant's hat back on to talk about Japan's hospitable stance on proposed cell therapies. He provides an update on the meaning of the new law and discusses a small cohort of companies poised to reap the advantages.

Read full article... Read full article...

 


Companies

Wednesday, October 22, 2014

Follow the Baby Boom to Biotech Stock Profits / Companies / BioTech

By: TLSReport

In recent years, entrepreneurial therapists have comprised the fast-growing sector in outpatient physical therapy. But companies like Agility Health are beginning to seize acquisition opportunities and market share in this growing sector. Steven Davidson, CEO of Agility Health Inc., tells The Life Sciences Report how his company is innovating in the physical therapy space, improving patient care and clients' bottom lines through its management expertise and proprietary software, AgileRPM. With baby boomers aging and the Affordable Care Act increasing access to services, physical therapy just might be the safe haven sector to shield your portfolio from macroeconomic uncertainty.

Read full article... Read full article...

 


Companies

Friday, September 12, 2014

Apple’s Smartwatch May put Biotech on Silicon Valley Time / Companies / BioTech

By: John_Mauldin

By Patrick Cox

Tech sites are buzzing right now about the new Apple smartwatch and iPhone. Having been a part of or close to the tech industry for a long time, the excitement that builds over new products doesn’t normally move me much. This time, though, it’s a little different because of reports that the phone and watch will be integrated to support healthcare apps.

Read full article... Read full article...

 


Companies

Saturday, August 23, 2014

Oxaloacetate Feeds and GROWS Brain Cells - Alzheimers Cure? / Companies / BioTech

By: John_Mauldin

By Patrick Cox

Oxford Paper Shows Oxaloacetate Feeds and Grows Brain Cells

The headline above is good news for those of us who want to proactively protect our health and extend our lives. I remain pretty cynical about the vast majority of supplements that claim life-extension benefits, but this compound is one of the rare exceptions. Before describing this important paper, published by in the Oxford journal Human Molecular Genetics, let me explain a bit about oxaloacetate, which John Mauldin and I both take several times a day.

Read full article... Read full article...

 


Companies

Thursday, August 07, 2014

New Growth Ideas for Biotech Stock Investors / Companies / BioTech

By: TLSReport

Medical technology is intimately linked to regenerative medicine. You could say these industries have a thunder-and-lightning relationship—you can't have one without the other. Mark Landy, director of research for medical technology and regenerative medicine at Summer Street Research Partners, has staked out the intertwined sectors as his universe of coverage. In this interview with The Life Sciences Report, Landy discusses three companies with very distinct capabilities that could bring extraordinary rewards to investors who understand the value propositions.

Read full article... Read full article...

 


Companies

Friday, August 01, 2014

Turning a Clinical Eye on Biotech Stocks with High Potential Investor Reward / Companies / BioTech

By: TLSReport

A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings and take on informed risk hold a short list of companies with huge potential. James, a senior analyst and managing director at Brinson Patrick Securities, is a neurosurgeon by training, and examines new platforms and proposed therapies with a clinician's eye. In this interview with The Life Sciences Report, James turns that eye on three names with dramatic, paradigm-changing technology platforms that could energize portfolios.

Read full article... Read full article...

 


Companies

Wednesday, July 02, 2014

The BioScience Stocks Profit Outlook for the Rest of 2014 / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.

That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.

That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.

Read full article... Read full article...

 


Companies

Monday, June 30, 2014

How to Tap Big Profits in That "Other" Bioscience Niche / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if you don't have someone knowledgeable to guide you.

And it's true. Putting your money behind new, experimental drugs, without some guidance, is a crapshoot.

But there's an approach to making profits from this sector that doesn't rely on breakthrough discoveries, expensive drug trials, or constant cash infusions through dilutive public offerings to fuel its engine.

Read full article... Read full article...

 


Companies

Wednesday, June 18, 2014

Not Even Washington's Meddling Could Stop Biotech’s Biggest Comeback / Companies / BioTech

By: Money_Morning

Michael A. Robinson writes: Late last month, I told you that biotech is one of the best ways to profit from the tech rebound. In fact, it was my “No Doz Opportunity No. 1.”

Somewhat ironically, a rollover in the biotech market was one of the proximate causes of the overall selloff in tech earlier this year.

And now I’m recommending that you invest in the company that purportedly “caused” the biotech market to roll over in the first place.

Read full article... Read full article...

 


Companies

Tuesday, June 10, 2014

Profit From the "Scariest Event" in Bioscience / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs-down for an experimental drug as it makes its way through the regulatory process.

Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.

Perhaps the least understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.

Read full article... Read full article...

 


Companies

Saturday, May 24, 2014

Healing the Blind… and Boosting Your Stocks Portfolio / Companies / BioTech

By: Casey_Research

By Chris Wood, Senior Analyst

Vision is one of the most important elements of our life, if not the most important one. A 2010 survey by Surge Research found that 60% of Americans are more afraid of blindness than of heart disease, the primary killer of both men and women in the United States.

Read full article... Read full article...

 


Companies

Friday, May 23, 2014

Four Telltale Signs of a Bioscience "Blockbuster" Biotech Stock in the Making / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.

Read full article... Read full article...

 


Companies

Wednesday, April 30, 2014

Biotech - New Melanoma Therapies Are Ready for Primetime / Companies / BioTech

By: TLSReport

Melanoma confronts patients and their physicians with unique barriers to treatment and successful outcomes. In this interview with The Life Sciences Report, Dr. Sanjiv Agarwala, chief of medical oncology and hematology at St. Luke's University Hospital, illuminates some of the new paradigms being developed in the treatment of this deadly skin cancer. Along the way, he spotlights interesting work in the field.

The Life Sciences Report: You have been a principal investigator in several different clinical trials exploring skin cancers and their metastatic manifestations. Because of your position at a major teaching institution, do you see mostly advanced-stage or late-stage patients? Are you ever able to see early-stage or treatment-naďve patients?

Read full article... Read full article...

 


Companies

Friday, April 25, 2014

Biotech Long-Term Profit Machines Stock Prices on Sale / Companies / BioTech

By: Money_Morning

Michael A. Robinson writes: Market volatility has suddenly created some great opportunities, including those in the biotech sector.

Supporting the inevitable ascent of the industry is the release of a steady stream of compounds that have helped them rack up billions in new revenue.

Consider that since it began trading in early 2001, the iShares Nasdaq Biotechnology Index (Nasdaq: IBB) is up 130%. That's more than triple the S&P 500's 13-year return of 43%.

Read full article... Read full article...

 


Companies

Friday, April 18, 2014

Build Biotech Wealth on Solid Platforms / Companies / BioTech

By: TLSReport

Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination.

The Life Sciences Report: As an analyst you focus on promising junior biotechs. What primary qualities do you look for in a company that you rate hold or outperform? And what do you think makes a junior biotech attractive to someone who might want to acquire it?

Read full article... Read full article...

 


Companies

Thursday, April 17, 2014

Hidden Australian Life Sciences Bio-tech Growth Stocks / Companies / BioTech

By: TLSReport

To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement.

The Life Sciences Report: You are based in Brisbane, Australia, where your firm, Morgans Financial, is headquartered. All the names on your coverage list have traded on the Australian Securities Exchange (ASX). How would you compare investing in Australian biotech or medtech stocks to investing in those same types of stocks in the U.S. or Europe?

Read full article... Read full article...

 


Page << | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | >>